Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Telix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $6.69 billion
P/E Ratio 1,237.89
Dividend Yield 0.00%
Shares Outstanding 334.23 million
Earnings per share 0.016
Dividend per share N/A
Year To Date Return 97.72%
Earnings Yield 0.08%
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Telix Pharmaceuticals Ltd (ASX: TLX)
    Latest News

    Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
    Healthcare Shares

    Telix share price hits record high on strong quarter and guidance upgrade

    This market darling has continued to deliver stunning top line growth.

    Read more »

    Doctor doing a telemedicine using laptop at a medical clinic
    Healthcare Shares

    Up 66% in FY24, will Telix Pharmaceuticals shares continue?

    After such an impressive run, has the trend exhausted?

    Read more »

    Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    ASX investors enjoyed a day to remember this Thursday...

    Read more »

    Man pointing at a blue rising share price graph.
    Share Gainers

    3 ASX All Ords shares rocketing over 10% today

    Investors are buying these shares with fever today.

    Read more »

    two men smiling with a laptop in front of them, symbolising a rising share price.
    Share Gainers

    Why Ora Banda, Paladin Energy, Seven Group, and Telix shares are charging higher

    These shares are shining brightly on Thursday. But why?

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Record Highs

    CBA and 7 other ASX 200 shares smashing new highs on Thursday

    Shareholders of these stocks will be smiling widely today.

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Record Highs

    Why is the Telix Pharmaceuticals share price rocketing 15% to a record high?

    Good news out of the United States is giving this radiopharmaceuticals stock a boost.

    Read more »

    Three health professionals at a hospital smile for the camera.
    Share Gainers

    Best 3 ASX 200 healthcare shares for price growth in FY24

    In terms of share price gains, this trio of healthcare companies is in rude health.

    Read more »

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was another day to forget for ASX investors this Tuesday.

    Read more »

    Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
    Broker Notes

    9 ASX All Ords shares lifted to 'strong buy' consensus ratings in June

    The ASX All Ords index is comprised of 500 stocks, and 80 were upgraded to strong buy ratings last month.

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    Bell Potter names the best ASX healthcare stocks to buy in FY25

    These stocks could bring your portfolio to life in the new financial year.

    Read more »

    A bored man sits at his desk, flat after seeing the latest news on the share market.
    Share Market News

    Here are the top 10 ASX 200 shares today

    It was a bleak Wednesday for many ASX shares today.

    Read more »

    Frequently Asked Questions

    No, Telix does not pay dividends at this time. 

    Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.

    TLX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Telix Pharmaceuticals Ltd

    Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.

    Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe. 

    The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States. 

    TLX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Jul 2024 $20.00 $0.07 0.35% 1,441,090 $20.20 $20.30 $19.86
    16 Jul 2024 $19.93 $-0.01 -0.05% 1,504,653 $19.77 $20.47 $19.66
    15 Jul 2024 $19.94 $0.01 0.05% 2,514,485 $20.10 $20.54 $19.79
    12 Jul 2024 $19.93 $0.54 2.78% 2,708,570 $19.49 $20.00 $18.97
    11 Jul 2024 $19.39 $1.84 10.48% 4,509,867 $19.85 $20.16 $19.18
    10 Jul 2024 $17.55 $-0.45 -2.50% 1,248,442 $17.90 $17.95 $17.42
    09 Jul 2024 $18.00 $0.00 0.00% 964,831 $18.07 $18.15 $17.92
    08 Jul 2024 $18.00 $-0.48 -2.60% 940,309 $18.30 $18.44 $17.97
    05 Jul 2024 $18.48 $0.30 1.65% 683,548 $18.10 $18.48 $17.97
    04 Jul 2024 $18.18 $-0.14 -0.76% 650,734 $18.45 $18.64 $18.01
    03 Jul 2024 $18.32 $-0.03 -0.16% 679,710 $18.35 $18.53 $18.16
    02 Jul 2024 $18.35 $0.26 1.44% 681,258 $18.05 $18.40 $18.03
    01 Jul 2024 $18.09 $-0.56 -3.00% 1,117,575 $18.46 $18.55 $17.97
    28 Jun 2024 $18.65 $0.25 1.36% 2,643,948 $18.56 $18.81 $18.43
    27 Jun 2024 $18.40 $-0.51 -2.70% 1,119,885 $18.67 $18.80 $18.34
    26 Jun 2024 $18.91 $0.05 0.27% 871,349 $18.70 $19.02 $18.65
    25 Jun 2024 $18.86 $0.58 3.17% 1,194,014 $18.40 $18.91 $18.12
    24 Jun 2024 $18.28 $-0.16 -0.87% 749,134 $18.36 $18.36 $18.01
    21 Jun 2024 $18.44 $0.30 1.65% 2,329,626 $18.25 $18.46 $17.91
    20 Jun 2024 $18.14 $0.19 1.06% 1,181,697 $17.98 $18.17 $17.67
    19 Jun 2024 $17.95 $0.75 4.36% 1,616,849 $17.45 $18.44 $17.45
    18 Jun 2024 $17.20 $0.00 0.00% 1,140,112 $16.76 $17.32 $16.76

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Jun 2024 Christian Behrenbruch Issued 144,037 $856,158
    As advised by the company. Non - Cash, Black Scholes, 403,977 Rights
    18 Jan 2024 Christian Behrenbruch Buy 153,298 $1,686,278
    Exercise of options. Estimated Valuation
    18 Jan 2024 Christian Behrenbruch Cancelled 46,702 $513,722
    Cancellation of securities. 46,702 options were forfeited
    18 Jan 2024 Christian Behrenbruch Exercise 153,298 $1,686,278
    Exercise of options. Estimated Valuation

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Harry Kevin McCann Non-Executive ChairmanNon-Executive Director Sep 2017
    Mr McCann has Board experience with some of Australia's companies. He is a former corporate lawyer and Chairman and Director of listed private and government companies, and government agencies. Mr McCann's expertise in shaping culture (including through organisational and remuneration design), public policy, social performance and stakeholder engagement, enables him to bring insights in these areas. He previously served as Chairman of Macquarie Group and Macquarie Bank Limited (from December 1996 to March 2016), Origin Energy Limited (from January 2000 to October 2013) and the Sydney Harbour Federation Trust (from June 2001 to June 2010 and from June 2015 to June 2018). He was also previously a Director of Bluescope Steel Ltd (from May 2002 to April 2013) and E&P Financial Group Limited (from February 2020 to November 2021). He was also a Director of the U.S. Studies Centre at the University of Sydney (from June 2010 to June 2020) and was a Trustee of the Sydney Opera House (from January 2018 to December 2023). Currently, Mr McCann is a Member of Champions of Change Founding Group (since April 2010), Chairman of Sydney Harbour Foundation Management (since August 2015), Chairman of China Matters (since November 2018), a Director of Haydn Ensemble (since December 2020), and Chair and Board Advisor of Blueprint Institute (since June 2022). Mr McCann practised as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He was made an Officer of the Order of Australia for services to business, corporate governance and gender equality in January 2020. He is member of risk committee and chair of People, Culture and Disclosure Committee.
    Ms Jann E Skinner Non-Executive Director Jun 2018
    Ms Skinner has financial acumen, accounting and auditing expertise, with an understanding of risk management compliance frameworks and control oversight. Her listed company experience and expertise in capital management and corporate development enable her to challenge management constructively. Ms Skinner has experience in auditing, accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She has served as an independent Non-Executive Director of QBE Insurance Group Limited (since October 2014) and a Director of Create Foundation Limited (since June 2004). She also served as a Director of HSBC Bank Australia Limited (from April 2017 to April 2023). SHe is member of People, Culture Committee and Disclosure Committee and chair of Risk Committee.
    Dr Christian Peter Behrenbruch Chief Executive OfficerManaging Director Jan 2017
    Dr Behrenbruch has radiopharmaceuticals experience and a track record in global healthcare and biotechnology entrepreneurship and technology commercialisation. Dr Behrenbruch has a focus on purpose and values-leadership and is versed in all aspects of running a publicly listed company as both CEO and Director in the U.S. and Australia. Previously, Dr Behrenbruch served as Chief Executive Officer at Mirada Solutions (now Mirada Medical Limited) (from July 2001 to December 2002), President at CTI Molecular Imaging (now Siemens Healthcare) (from August 2003 to September 2006), Chief Executive Officer at Fibron Technologies, Inc. (from June 2008 to December 2011) and Chief Executive Officer at ImaginAb, Inc. (from October 2007 to February 2015). He served as a Director at Siemens Molecular Imaging Ltd (from May 2005 to September 2006), Momentum Biosciences LLC (from July 2007 to June 2009), Radius Health Ltd (now Adaptix Ltd) (from May 2009 to February 2011). Dr Behrenbruch was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) (from October 2012 to July 2014). He is member of Disclosure Committee.
    Dr Andreas Kluge Non-Executive Director Jan 2017
    Dr Kluge's clinical research and development experience in radiochemistry, molecular imaging and clinical development is valued by the Board. He brings a critical mind to the requirements of clinical development of novel radionuclide-based products and devices to enable clinical trials and commercialisation. He is a registered physician and the author of patents and publications in the field of nuclear medicine, neurology, infection and immunology. Dr Kluge is a Founder, General Manager and Medical Director of ABX CRO Advanced Pharmaceutical Services GmbH (since August 2002), a full service Contract Research Organisation (CRO) for Phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He was also a Founder and founding CEO of ABX GmbH ( (from September 1996 to July 2002), one of the manufacturers of radiopharmaceutical precursors globally.
    Dr Mark Alexander Nelson Non-Executive Director Sep 2017
    Dr Nelson has experience in the investment community, including in life sciences. Dr Nelson has served as Chairman of the Caledonia Investments Group (since January 2012) and as a Director of The Caledonia Foundation (since August 2002). He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group (from February 1992 to January 2012). Dr Nelson has served as Chairman of Art Exhibitions Australia (since 2019), Director of the Mindgardens Neuroscience Network (since February 2018), Governor of the Florey Neurosciences Institute (since October 2007), and Director of Kaldor Public Art Projects (since October 2005). He is member of People, Culture and Risk Committee.
    Ms Tiffany Olson Non-Executive Director Mar 2022
    Ms Olson brings experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceuticals sector. Ms Olson's most recent executive role was with Cardinal Health, the largest provider of radiopharmaceuticals in the U.S.. As President of Cardinal Health Nuclear & Precision Health Solutions (from July 2013 to October 2021), overseeing Cardinal's radiopharmaceutical manufacturing and nuclear pharmacy network, she led a business transformation that increased market share and profit growth. Prior to Cardinal Health, Ms Olson served as President of NaviMed (from August 2011 to July 2013), as Vice President Diagnostics at Eli Lilly and Company (from November 2009 to July 2011), and as President and Chief Executive Officer at Roche Diagnostics Corporation (from June 2005 to May 2008). Previously she was a Director at Asuragen, Inc (from August 2016 to March 2021) and at BioTelemetry, Inc. (from February 2019 to February 2021). She currently serves as a Director of Castle Biosciences, Inc. (since April 2021), an Advisory Board member at Langham Logistics (since August 2021), a Director at Education and Research Foundation, Nuclear Medicine & Molecular Imaging (since April 2022) and a Partner at Trusted Health Advisors (since August 2023). She is member of Risk Committee.
    Ms Genevieve Ryan Company Secretary Dec 2022
    Genevieve Ryan Company Secretary
    Richard Valeix Group Chief Commercial Officer
    Darren Smith Group Chief Financial Officer
    Colin Hayward PhD Group Chief Medical Officer

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees ( Limited 38,850,342 11.99%
    J P Morgan Nominees Australia Pty Limited 34,966,849 10.79%
    Citicorp Nominees Pty Limited 29,118,387 8.99%
    Elk River Holdings Pty Ltd As Trustee For The Behrenbruch Family Trust And C Behrenbruch 22,675,000 7.00%
    Gnosis Verwaltungsgesellschaftm B H 22,675,000 7.00%
    National Nominees Limited 11,451,177 3.53%
    Grand Decade Developments Limited 10,947,181 3.38%
    Uv Cap Gmbh & Co Kg 7,454,500 2.30%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 6,623,660 2.04%
    Bnp Paribas Noms Pty Ltd 6,279,603 1.94%
    Bnp Paribas Nominees Pty Ltd i 5,978,960 1.85%
    The Oncidium Foundation 5,929,331 1.83%
    Hsbc Custody Nominees (Australia) Limited A/C 2 4,017,015 1.24%
    Lightpoint Medical Ltd 3,298,073 1.02%
    Man Holdings Pty Ltd 3,228,750 1.00%
    BNP Paribas Nominees Pty Ltd II 2,922,383 0.90%
    Pacific Custodians Pty Limited 1,990,000 0.61%
    Yelwac Pty Ltd 1,981,804 0.61%
    Netwealth Investments Limited 1,943,357 0.60%
    UBS Nominees Pty Ltd 1,838,727 0.57%
    Aglub Holdings Pty Ltd 1,733,342 0.54%